{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:58:40Z","timestamp":1790787520723,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970180"],"award-info":[{"award-number":["81970180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Project of Tianjin Municipal Health Committee","award":["TJWJ2022QN030"],"award-info":[{"award-number":["TJWJ2022QN030"]}]},{"name":"Science and Technology Project of Tianjin Municipal Health Committee","award":["TJWJ2022XK018"],"award-info":[{"award-number":["TJWJ2022XK018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-03998-1","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:43:54Z","timestamp":1742013834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Infectious complications distribution following CLL1 CAR-T cell therapy for acute myeloid leukemiass"],"prefix":"10.1007","volume":"74","author":[{"given":"Jianmei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"3998_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","volume":"19","author":"O Bupha-Intr","year":"2021","unstructured":"Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B (2021) CAR-T cell therapy and infection: a review. Expert Rev Anti Infect Ther 19:749\u2013758. https:\/\/doi.org\/10.1080\/14787210.2021.1855143","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3998_CR2","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.Can-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB, van den Oudenrijn S, Bakker AQ et al (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 64:8443\u20138450. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-1659","journal-title":"Cancer Res"},{"key":"3998_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W et al (2018) CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol 11:7. https:\/\/doi.org\/10.1186\/s13045-017-0553-5","journal-title":"J Hematol Oncol"},{"key":"3998_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R et al (2022) First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol 15:88. https:\/\/doi.org\/10.1186\/s13045-022-01308-1","journal-title":"J Hematol Oncol"},{"key":"3998_CR5","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang H, Bu C, Peng Z et al (2022) Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia 36:2596\u20132604. https:\/\/doi.org\/10.1038\/s41375-022-01703-0","journal-title":"Leukemia"},{"key":"3998_CR6","first-page":"615","volume":"12","author":"YJ Ma","year":"2022","unstructured":"Ma YJ, Dai HP, Cui QY et al (2022) Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am J Cancer Res 12:615\u2013621","journal-title":"Am J Cancer Res"},{"key":"3998_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA et al (2018) Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131:121\u2013130. https:\/\/doi.org\/10.1182\/blood-2017-07-793760","journal-title":"Blood"},{"key":"3998_CR8","doi-asserted-by":"publisher","first-page":"ofaa21","DOI":"10.1093\/ofid\/ofaa121","volume":"7","author":"SB Vora","year":"2020","unstructured":"Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA (2020) Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults. Open Forum Infect Dis 7:ofaa21. https:\/\/doi.org\/10.1093\/ofid\/ofaa121","journal-title":"Open Forum Infect Dis"},{"key":"3998_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK (2018) Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis 67:533\u2013540. https:\/\/doi.org\/10.1093\/cid\/ciy152","journal-title":"Clin Infect Dis"},{"key":"3998_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","volume":"7","author":"H Luo","year":"2019","unstructured":"Luo H, Wang N, Huang L et al (2019) Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer 7:271. https:\/\/doi.org\/10.1186\/s40425-019-0767-x","journal-title":"J Immunother Cancer"},{"key":"3998_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","volume":"10","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Palomba ML, Pennisi M et al (2020) Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J 10:79. https:\/\/doi.org\/10.1038\/s41408-020-00346-7","journal-title":"Blood Cancer J"},{"key":"3998_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102713","author":"E Atilla","year":"2023","unstructured":"Atilla E, Benabdellah K (2023) The black hole: CAR T cell therapy in AML. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15102713","journal-title":"Cancers (Basel)"},{"key":"3998_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R et al (2023) Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21:503\u2013513. https:\/\/doi.org\/10.6004\/jnccn.2023.0025","journal-title":"J Natl Compr Canc Netw"},{"key":"3998_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"3998_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pbc.25335","volume":"62","author":"GM Haeusler","year":"2015","unstructured":"Haeusler GM, Phillips RS, Lehrnbecher T, Thursky KA, Sung L, Ammann RA (2015) Core outcomes and definitions for pediatric fever and neutropenia research: a consensus statement from an international panel. Pediatr Blood Cancer 62:483\u2013489. https:\/\/doi.org\/10.1002\/pbc.25335","journal-title":"Pediatr Blood Cancer"},{"key":"3998_CR16","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA et al (2020) Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis 71:1367\u20131376. https:\/\/doi.org\/10.1093\/cid\/ciz1008","journal-title":"Clin Infect Dis"},{"key":"3998_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.bbmt.2007.08.049","volume":"13","author":"JA van Burik","year":"2007","unstructured":"van Burik JA, Carter SL, Freifeld AG et al (2007) Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 13:1487\u20131498. https:\/\/doi.org\/10.1016\/j.bbmt.2007.08.049","journal-title":"Biol Blood Marrow Transplant"},{"key":"3998_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","volume":"22","author":"JH Young","year":"2016","unstructured":"Young JH, Logan BR, Wu J et al (2016) Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transplant 22:359\u2013370. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"3998_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol 13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153","journal-title":"Front Immunol"},{"key":"3998_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","volume":"45","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, Isgr\u00f2 V, Cutroneo PM, Ferrajolo C, Cirillo V, Del Bufalo F, Raschi E, Poluzzi E, Trifir\u00f2 G (2022) Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf 45:891\u2013908. https:\/\/doi.org\/10.1007\/s40264-022-01194-z","journal-title":"Drug Saf"},{"key":"3998_CR21","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/jco.20.00158","volume":"38","author":"T Lehrnbecher","year":"2020","unstructured":"Lehrnbecher T, Fisher BT, Phillips B et al (2020) Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol 38:3205\u20133216. https:\/\/doi.org\/10.1200\/jco.20.00158","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s00262-025-04066-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03998-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03998-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03998-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:02:04Z","timestamp":1749063724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03998-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["3998"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03998-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4227895\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"6 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-025-04066-4","URL":"https:\/\/doi.org\/10.1007\/s00262-025-04066-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Tianjin First Center Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"149"}}